A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Delayed graft function
  • Focus Registrational; Therapeutic Use
  • Acronyms ReGIFT
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 This study was discontinued in Netherlands according to European Clinical Trials Database record.
    • 28 Mar 2017 According to a Silence Therapeutics media release, data readout from this trial is expected in third quarter of 2018.
    • 14 Mar 2016 According to a Quark Pharmaceuticals media release, the company has dosed the first patients in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top